Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA.
Anticancer Res
; 40(11): 6319-6325, 2020 Nov.
Article
en En
| MEDLINE
| ID: mdl-33109569
ABSTRACT
BACKGROUND:
Attempts have been made to enhance systemic therapy for osteosarcoma. In our previous study, the systemic administration of a vesicular stomatitis virus (VSV) improved the survival rates of mice with osteosarcoma but did not improve the long-term survival of the animals. MATERIALS ANDMETHODS:
In the present study, we developed a novel oncolytic VSV by incorporating tumor-suppressor microRNA143 (rVSV-miR143) to compare the antitumor effects of various doses (10×10-4, 5×10-4, and 1×10-4 multiplicity of infection) of rVSV-miR143 with those of VSV in vitro.RESULTS:
The cytotoxicity and migration-inhibitory effects of rVSV-miR143 on the osteosarcoma cells were significantly higher than those of VSV alone at a dose of 5×10-4 multiplicity of infection, indicating that rVSV-miRNA143 enhances the antitumor effect at certain doses.CONCLUSION:
VSV incorporating tumor-suppressor miRNA143 demonstrated a synergistic antitumor effect on osteosarcoma cells in vitro.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Recombinación Genética
/
Genes Supresores de Tumor
/
Virus de la Estomatitis Vesicular Indiana
/
MicroARNs
/
Virus Oncolíticos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Anticancer Res
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón